Mereo BioPharma Net Worth
Mereo BioPharma Net Worth Breakdown | MREO |
Mereo BioPharma Net Worth Analysis
Mereo BioPharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Mereo BioPharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Mereo BioPharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Mereo BioPharma's net worth analysis. One common approach is to calculate Mereo BioPharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Mereo BioPharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Mereo BioPharma's net worth. This approach calculates the present value of Mereo BioPharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Mereo BioPharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Mereo BioPharma's net worth. This involves comparing Mereo BioPharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Mereo BioPharma's net worth relative to its peers.
Enterprise Value |
|
To determine if Mereo BioPharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Mereo BioPharma's net worth research are outlined below:
| Mereo BioPharma generated a negative expected return over the last 90 days | |
| Mereo BioPharma has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 10 M. Net Loss for the year was (29.47 M) with profit before overhead, payroll, taxes, and interest of 936 K. | |
| Mereo BioPharma Group currently holds about 94.3 M in cash with (21.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.81. | |
| Mereo BioPharma has a frail financial position based on the latest SEC disclosures | |
| Roughly 66.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: MEREO BIOPHARMA Upgraded to Buy What Does It Mean for the Stock |
Mereo BioPharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Mereo BioPharma Group. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Mereo BioPharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Mereo BioPharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Mereo BioPharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mereo BioPharma Group backward and forwards among themselves. Mereo BioPharma's institutional investor refers to the entity that pools money to purchase Mereo BioPharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2024-12-31 | 2.6 M | Tejara Capital Ltd | 2024-12-31 | 2.3 M | Goldman Sachs Group Inc | 2024-12-31 | 2.1 M | Renaissance Technologies Corp | 2024-12-31 | 1.2 M | Great Point Partners Llc | 2024-12-31 | 1.1 M | Perceptive Advisors Llc | 2024-12-31 | 1.1 M | Integral Health Asset Management, Llc | 2024-12-31 | 1000 K | Ubs Asset Mgmt Americas Inc | 2024-12-31 | 964.9 K | Tema Etfs | 2024-12-31 | 890.5 K | Hhg Plc | 2024-12-31 | 17.1 M | Rubric Capital Management Lp | 2024-12-31 | 15.3 M |
Follow Mereo BioPharma's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 630.8 M.Market Cap |
|
Project Mereo BioPharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.52) | (0.54) | |
| Return On Capital Employed | (0.45) | (0.47) | |
| Return On Assets | (0.51) | (0.54) | |
| Return On Equity | (0.52) | (0.50) |
When accessing Mereo BioPharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Mereo BioPharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Mereo BioPharma's profitability and make more informed investment decisions.
Evaluate Mereo BioPharma's management efficiency
Mereo BioPharma Group has return on total asset (ROA) of (0.2386) % which means that it has lost $0.2386 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4847) %, meaning that it created substantial loss on money invested by shareholders. Mereo BioPharma's management efficiency ratios could be used to measure how well Mereo BioPharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of March 2025, Return On Tangible Assets is likely to drop to -0.54. In addition to that, Return On Capital Employed is likely to drop to -0.47. At this time, Mereo BioPharma's Total Assets are very stable compared to the past year. As of the 22nd of March 2025, Net Tangible Assets is likely to grow to about 45.6 M, while Non Current Assets Total are likely to drop about 2.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.09 | 0.08 | |
| Tangible Book Value Per Share | 0.09 | 0.08 | |
| Enterprise Value Over EBITDA | (64.96) | (68.21) | |
| Price Book Value Ratio | 5.43 | 5.70 | |
| Enterprise Value Multiple | (11.18) | (11.73) | |
| Price Fair Value | 5.43 | 5.70 | |
| Enterprise Value | 1.3 B | 1.4 B |
Mereo BioPharma Group benefits from a proactive management team that anticipates market trends. Our analysis delves into how this proactive stance influences financial metrics and stock valuation.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Mereo BioPharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Mereo BioPharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Mereo BioPharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mereo BioPharma Corporate Filings
| 12th of February 2025 Other Reports | ViewVerify | |
F4 | 6th of February 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 23rd of January 2025 Other Reports | ViewVerify | |
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Mereo BioPharma Earnings per Share Projection vs Actual
Mereo BioPharma Corporate Management
| Christine CPA | Chief Officer | Profile | |
| Bo Kara | Senior CMC | Profile | |
| Fiona Bor | Head Property | Profile | |
| Jackie Parkin | Therapy Endocrinology | Profile | |
| MBBS MD | CoFounder Strategy | Profile | |
| John Lewicki | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Mereo BioPharma Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mereo BioPharma. If investors know Mereo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mereo BioPharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Mereo BioPharma Group is measured differently than its book value, which is the value of Mereo that is recorded on the company's balance sheet. Investors also form their own opinion of Mereo BioPharma's value that differs from its market value or its book value, called intrinsic value, which is Mereo BioPharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mereo BioPharma's market value can be influenced by many factors that don't directly affect Mereo BioPharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mereo BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mereo BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mereo BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.